The Single-cell Kits industry trends over the past 18 months reflect rapid innovation driven by advancements in genomic research and precision medicine. Strategic partnerships have emerged as a key growth lever, with companies like 10x Genomics collaborating with academic institutions to optimize single-cell RNA-sequencing workflows. Notable mergers & acquisitions include Thermo Fisher Scientific’s acquisition of PacBio, enhancing its single-cell multi-omics portfolio. Product/technology launches dominated 2023, such as Illumina’s release of the NovaSeq Xp System, which integrates single-cell ATAC-seq capabilities for deeper epigenetic insights. Regulatory shifts, including the FDA’s revised guidelines for single-cell therapeutics in 2024, have spurred demand for compliant kits. Enterprises are increasingly adopting automation-friendly kits to address labor shortages, while funding rounds totaling over $500M in 2023–2024 supported startups like Singular Bio and CellCarta in expanding their spatial transcriptomics offerings. These dynamics underscore a market prioritizing scalability, AI-driven data analysis, and cross-sector R&D synergies.
